VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.

NCT07642453 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Venetoclax,Azacitidine,Arubicin,Cytarabine,G-CSF.

Sponsor

Hematology department of the 920th hospital